

Combined Metronomic Chemo-Immunotherapy for Metastatic Esophageal Carcinoma in Second-Line and Beyond

Mahesh Kallolli

Department of Surgical Oncology, J N Medical College, Belagavi, Karnataka, India.

Irappa V Madabhavi

Department of Medical and Pediatric Oncology, J N Medical College, Belagavi, Kerudi Cancer Hospital, Bagalkot, Nanjappa Hospital, Davanagere and Dr. N B Patil, Gadag, Karnataka, India.

Chidanand Chavan

Department of Radiology, Lakeview Hospital, Belgaum, Karnataka, India.

Swaroop Revannasiddaiah

Department of Medical Oncology, Sagar Hospitals, Bengaluru, Karnataka, India.

Ishu Gupta

Department of Medical Oncology, Fortis Hospital, Noida, India.

Malay S. Sarkar

Department of pulmonary medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.

Background and objective: Approximately 570,000 new cases of esophageal cancer are diagnosed worldwide annually, resulting in approximately 510,000 deaths per year. Currently, there are no effective second-line treatments for patients who progress on cisplatin and 5-fluorouracil. Esophageal squamous cell carcinomas and adenocarcinomas have proven to be inherently resistant to systemic treatments due to histological, molecular, and etiological heterogeneity, resulting in limited responses after first-line therapy.

Materials and Methods: We present three case reports of patients (a 57-year-old male, a 53-year-old male, and a 47-year-old female) who presented with dysphagia for solid foods, weight loss, and dyspepsia for 1 month, 3 months, and 1.5 months, respectively. Upper gastroesophageal endoscopy revealed ulcerated, friable lesions with minimal luminal compromise. Biopsies confirmed poorly differentiated adenocarcinoma (PDAC) in all three cases. Positron emission tomography-computed tomography (PET-CT) showed FDG-avid lesions in the gastroesophageal junction, gastric cardia, multiple retroperitoneal lymph nodes, and bilateral liver lesions. All three patients had stage IV disease with PDAC (two patients) and squamous cell carcinoma (one patient). The first patient received a DOX regimen containing docetaxel, oxaliplatin, and capecitabine at 2-week intervals. After four cycles, he demonstrated stable disease in the gastroesophageal junction and liver, with a slight increase in retroperitoneal lymph node size. The second and third patients received a paclitaxel-carboplatin protocol. After six cycles, both patients achieved a partial response and were subsequently managed with six cycles of CAPOX as second-line chemotherapy. Both patients exhibited progressive disease after five and six months of second-line chemotherapy, respectively.

Results: In light of radiological progression, the first patient was initiated on intravenous nivolumab (240 mg every two weeks) along with low-dose capecitabine (500 mg twice a day). After four cycles of treatment, a PET-CT scan showed complete metabolic response in the gastroesophageal junction, liver, and retroperitoneal lesions. The patient continues to receive nivolumab and low-dose capecitabine, with a treatment plan of two years.

Conclusion: This case series suggests that nivolumab combined with metronomic

chemotherapy using low-dose capecitabine is well-tolerated and exhibits antitumor activity in extensively pre-treated patients with metastatic esophageal poorly differentiated adenocarcinoma. Further studies investigating nivolumab, metronomic chemotherapy, and immuno-immuno combination therapy for these diseases are ongoing.

Introduction

The promise of immunotherapy in esophago-gastric cancer has been suggested for a long time due to the recognized link between infection, chronic inflammation, and malignancy. The emerging clinical trial data is somewhat confusing but it appears that anti programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibodies do demonstrate some efficacy in a minority of gastroesophageal cancer patients with metastatic disease. Recent phase III data from the Keynote 059 and Attraction 2 studies demonstrate response rates of approximately 12% in a population of heavily pretreated patients and there was an overall survival benefit in the Attraction 2 trial [1,2].

Promising immunotherapy approaches, such as chimeric antigen receptor (CAR) T cell therapy and therapeutic blockade of immune checkpoints, in particular cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death protein 1 pathway (PD-1/ PD-L1), have boosted the development of new therapeutic regimens for patients with metastatic esophageal cancer. Immune blockade of the PD-1/PD-L1 interaction by monoclonal antibodies can restore the antitumor activity of cytotoxic T cells. Early clinical trials using two anti-PD-1 antibodies (nivolumab and pembrolizumab), and three anti-PD-L1 antibodies (avelumab, durvalumab, and atezolizumab), have shown great promise [3].

Case Vignette

Fifty-seven-year-old man with history of diabetes, non-smoker and non-alcoholic by habits came with history of dysphagia for solid foods, weight loss and dyspepsia for 1 month. On examination there was mild pallor and moderate hepatomegaly. His routine investigations revealed hemoglobin of 10.3gm/dl, total count of 8700/ cu mm and platelet count of 292000/cu.mm. Erythrocyte sedimentation rate (ESR) was 70mm at first hour. Serology for human immunodeficiency virus, hepatitis B and C viruses were negative.

Upper gastro esophageal endoscopy shows ulcerated friable lesion at GE junction with minimal luminal compromise and biopsy was taken. His histopathology of gastro-esophageal biopsy specimen shows poorly differentiated adenocarcinoma and on Immunohistochemistry the tumor cells are diffusely positive for CK7 and show focal positivity for CEA and tumor cells are negative for P40 and P63. Computed Tomography (CT) scan of thorax and abdomen-pelvis shows heterogeneously enhancing circumferential wall thickening involving gastro-esophageal junction with few metastatic hypodense lesions showing heterogeneous enhancement in segment VII of right lobe of liver, in segment IVA and II of left lobe of liver along with peri-gastric and paraaortic lymphadenopathy. PET-CT shows FDG avid asymmetric gastric / gastroesophageal junction wall thickening up to 17mm involving its cardia and extending up to GE junction with standard uptake value (SUV) - 10.8, multiple FDG avid lymph nodes are seen in gastro-hepatic, portocaval, pericaval, peri-aortic and aorto-caval region and the largest measuring 22x13mm in aorto-caval region with SUV - 13.2 and multiple FDG avid heterogeneously enhancing focal lesions are seen in both lobes of liver, the largest measuring 33x31 mm in segment IV with SUV - 15.

Patient was managed with supportive care and the definitive treatment was done with DOX regimen containing Inj. Docetaxel 60mg per m² IV on D1, Inj.

Oxaliplatin 100mg per m² IV on D1 and Tab. Capecitabine 1000mg per m² orally twice daily

continuously with cycles repeated every 2 weekly. After 4 cycles of DOX regimen, CT scan of thorax and abdomen-pelvis shows stable disease in GE junction, liver and slightly increased size of retroperitoneal lymph nodes of around 18%. In view of radiological progression, after explaining about new treatment, we started him on Injection, Nivolumab 240mg intravenously every 2 weekly along with metronomic low dose capecitabine at 500mg twice daily regimen. After completion of 4 cycles of treatment his PET-CT showing significant interval reduction in soft tissue thickening and FDG uptake of lesion in gastric cardia and GE junction is noted with minimal soft tissue thickening in distal esophagus with no significant metabolic activity. Near total resolution of FDG avid liver lesions and lymph nodes in gastro hepatic ligament, porto- caval, peri caval, peri aortic and aorto caval region is noted. In view of very good response to combined Nivolumab and metronomic chemotherapy, we are continuing Nivolumab 240mg and low dose capecitabine at an interval of 2 weeks and planned to complete for 2 years or till progression of the disease. Now he is on regular treatment with 2 weekly nivolumab and metronomic chemotherapy and at the time of submission of this article he was completed 11th cycle of immunotherapy. Patient tolerated immunotherapy, very well without much intolerable side effects. Now he is continuing the same dose and schedule of nivolumab.

Second and third patients are, 53 year old man & 47 year old woman who, presented with dysphasia for solid foods, weight loss and dyspepsia since, 3 months & 1.5 months respectively. Upper gastro oesophageal endoscopy of both patients shows ulcerated friable lesion with minimal luminal compromise. Both patients were having stage IV disease, with squamous cell carcinoma & PDAC respectively. Second & 3rd patient was put on Pclitaxel-carboplatil protocol, after 6 cycles both were having partial response & was managed with 6 cycles CAPOX as second line chemotherapy. After 5th & 6th months of second line chemotherapy both patients were having progressive disease. In view of radiological progression, we started both patients on Injection, Nivolumab 240mg intravenously every 2 weekly along with low dose capecitabine 500mg twice a day. After 4 cycles of treatment both the patients PET-CT showing complete metabolic response in GE junction, liver and retroperitoneal lesions. Now we are continuing Nivolumab and low dose capecitabine planned to complete for 2 years.

Discussion

Esophageal cancer (EC) is the sixth most common cause of cancer-related death worldwide, with a 5-year survival rate of 5%–8% in patients with metastatic disease. First-line platinum-based doublet chemotherapy (CTX) provides a modest survival benefit in patients with metastatic squamous cell EC (mESCC), with a median OS of 7.6 months. Over 40% of patients with EC have PD-L1+ tumors, which are associated with worse OS outcomes. Nivolumab has received FDA approval for treatment of patients with several malignancies, including advanced lung cancer, melanoma, advanced kidney cancer, head and neck squamous cell cancer, advanced liver cancer, advanced bladder cancer, classical Hodgkin lymphoma and colorectal cancer. Nivolumab (NIVO), an anti-PD-1 mAb, demonstrated efficacy and a manageable safety profile in patients with ESCC. In the phase 2 ATTRACTION-1 trial, NIVO 3 mg/kg produced an ORR of 17% and median OS of 10.8 months in heavily pretreated patients with ESCC [4]. The programmed death-1 (PD-1) pathway is an immune checkpoint to attenuate T-cell-mediated immune responses and may be exploited by tumors to avoid immune surveillance. Immune blockade of the PD-1/PD-L1 interaction by monoclonal antibodies can restore the antitumor activity of cytotoxic T cells [5].

Results from a randomized, phase III study presented at 2017 Gastrointestinal Cancers Symposium, Investigators concluded that nivolumab was effective as the salvage treatment in pretreated patients with advanced gastric or gastro-esophageal junction cancer. It is the first randomised, phase III trial in which immunotherapy agent demonstrated improved survival in the setting in which currently there is no standard of care treatment [2].

In the international, multicenter, open-label, randomized ATTRACTION-3 trial, approximately 390

patients with esophageal cancer who were refractory to or intolerant of 1 prior combination therapy with fluoropyrimidine and platinum-based treatment received either nivolumab at 240 mg/body solution intravenously (IV) every 2 weeks or chemotherapy with docetaxel or paclitaxel until disease progression or severe adverse events (AEs). Docetaxel was administered at 75 mg/m² IV every 2 weeks and paclitaxel at 100 mg/m² weekly for 6 weeks followed by a 2-week treatment holiday. Preliminary results showed that the ORR was 17.2% (95% CI, 9.9%-28.2%) as of May 17, 2015. With the 2-year update, the ORR was 17.2% and the median DOR was 11.7 months. Kaplan-Meier estimates for 1-, 1.5-, and 2-year OS rates were 45.3%, 25.0%, and 17.2%, respectively. One-, 1.5, and 2-year PFS rates were 10.3%, 8.6%, and 8.6%, respectively [6].

One clinical trial with trial no NCT03278626, A Phase I/II Open Label Multi-Center Study of Immune Checkpoint Therapy With Nivolumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma comparing role of Nivolumab along with concurrent chemo-radiotherapy with weekly Paclitaxel 50mg per m² and Carboplatin AUC 2 along with radiation therapy will tell us the added role of nivolumab in locally advanced ESCC.

Several trials are currently studying the use of combination immune checkpoint inhibitors. The ongoing Checkmate-649 study [7] is assessing dual immune checkpoint inhibitors nivolumab plus ipilimumab versus combination chemotherapy (XELOX or FOLFOX) versus FOLFOX plus nivolumab in the first line setting of metastatic gastric or GEJ cancers (NCT02872116). The BMS Fraction-study (Fast Real-Time Assessment of Combination Targeted Immuno-Oncology) is a basket study assessing multiple IO-IO combinations including the combination of nivolumab plus ipilimumab, nivolumab plus relatlimab (LAG-3 inhibitor) or nivolumab plus BMS-986205 (IDO inhibitor) in advanced gastric/GEJ cancer (NCT 02935634). Similarly, the Roche-Genentech Morpheus study is an open-label umbrella study evaluating multiple immunotherapy based treatment combinations in patients with locally advanced, unresectable or metastatic gastric or GEJ cancers (NCT 03281369).

In conclusion, we clearly need a much greater immunologic/molecular understanding of biological phenomena that lead to the development and progression of esophageal cancer and a comprehensive analysis of the immune microenvironment not just in the metastatic setting but at various stages throughout a cancers lifespan. If single agent chemotherapy is a better strategy than single agent PD-1 inhibitors for the majority of patients then we clearly need to look at IO-IO combination strategies or combining PD-1 inhibitors with chemotherapy. These studies are ongoing and preliminary results are promising but the science needs to guide our clinical trial designs. We conclude that Nivolumab showed promising activity with a manageable safety profile. This drug could offer a potential new treatment approach for patients with treatment-refractory advanced esophageal carcinoma.

References

References

1. Fuchs CS, Doi T, Jang RW, et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. *J Clin Oncol*. 2017; 35
2. Kang YK, Boku N, Satoh T, Ryu M, Chao Y, Kato K, Chung HC, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet (London, England)*. 2017; 390(10111)[DOI](#)
3. Madabhavi I, Ks S, Sarkar M, Modi M. Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab. *International Journal of Hematology-Oncology and Stem Cell Research*. 2019; 13(2)



4. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. *The Lancet. Oncology*. 2017; 18(5)[DOI](#)
5. Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. *Immunotherapy*. 2014; 6(4)[DOI](#)
6. Kitagawa Y, Doki Y, Kato K, et al. Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07). *Ann Oncol*. 2017; 28(5). 2017; 28(5):mdx369.022. [DOI](#)
7. Janjigian Y, Adenis A, Aucoin J, et al. Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer. *JCO*. 2017.[DOI](#)